REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
X on X See what’s happening and join the conversation Continue with phone ...
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.